Browse by author
Lookup NU author(s): Dr Jess Dyson,
Dr Mark Hudson,
Dr Stuart McPhersonORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Patients with current or past hepatitis B virus (HBV) infection are at risk of viral reactivation if they receive immune-modulating treatment or chemotherapy. This can range from subclinical elevation in HBV DNA levels, to abnormal liver function tests, to severe hepatitis with liver failure and risk of death. All patients should be screened for hepatitis B with surface antigen and core antibody before receiving immunosuppression. Patients with positive hepatitis B serology should be referred for specialist advice. Prophylactic antiviral treatment is recommended for patients with current/past hepatitis B who receive immunosuppressive chemotherapy.
Author(s): Dyson JK, Hudson M, McPherson S
Publication type: Article
Publication status: Published
Journal: Clinical Medicine
Print publication date: 01/10/2014
ISSN (print): 1470-2118
ISSN (electronic): 1473-4893
Publisher: Royal College of Physicians
Altmetrics provided by Altmetric